Last updated: 2025/05/13
Homepage
Home
Customer Testimonials
Director of Quality Assurance
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
Solid-State Characterization/FAST
pKa/LogP/LogD Measurements
Stability and Solubility Studies
In-Silico PBPK Modeling and Simulation
API Form and Solid-State Research
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Crystallization Development Services
Crystallization Development
Chiral Separation
Pre-formulation Studies
Comprehensive Physicochemical Property Evaluation
Excipient Selection and Compatibility Studies
Formulations for PK/Efficacy/Tox Studies
Animal Dosing Vehicle Selection
Amorphous Solid Dispersions
Formulation and Analytical Development
Formulation Development
Oral Solid Dosage Forms
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Pediatric Formulation (Mini-tablet)
Analytical Chemistry
GMP Manufacturing
Clinical and Commercial Manufacturing
FIH-PMF-FMF Manufacturing
Clinical Supply
Lab Technician or Associate Scientist
Crystal Bio Solutions
Biologics CMC Analytical Services
Providing advanced Biologics Analytical Services
How do Biologics work and Why are they unique?
How are Biologics approved by FDA?
Categories of Biologics and Their Applications
Competitive Advantages
Seasoned Veterans Team
Advanced Analytical Capabilities
Regulatory Expertise
Quick Turnaround
Tailored Services
Client-Centric Flexibility
Lab & Equipment
Seasoned Veterans Team_copy20241119
Advanced Analytical Capabilities_copy20241119
Regulatory Expertise_copy20241119
Quick Turnaround_copy20241119
Tailored Services_copy20241119
Client-Centric Flexibility_copy20241119
Bioanalytical and Biomarker Services
Senior Scientist or Associate Principal Scientist in LCMS area
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
News
Improving the Manufacture of mRNA Biologics
CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
Dr. LianFeng Huang Joins Crystal Pharmatech as Chief Scientist
Crystal Formulation Services successfully passed the dual certification of GMP and GDP conducted by SGS
Industry Shift: FDA Goes Vegan?
Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services
Crystal Pharmatech Returned to AAPS 2022 PharmSci 360
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership
Crystal Pharmatech Raises $10 Million to Accelerate Growth
Crystal Formulation Services, Formulation Tailor-made for Your Molecules
Candoo Enables the Successful Development of a BCS 4 Combo Drug Product
International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location
Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs
Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions
Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development
Crystal Pharmatech Expands Leadership Team
Crystal Formulation Services（CFS）Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China
Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer
Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD
Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit
Events
AAPS 2024 PHarmSCi 360
Formulation & Delivery US 2024
The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco
SAPA Annual Conference (Gold Corporate Sponsorship)
14th American Drug Delivery and Formulation Summit (Exhibit)
2024 CASSS - Mass Spec Symposium
ChemOutsourcing 2024
Immuno-Oncology Summit 2024 - Meet Crystal Bio at Booth 15
The Bioprocessing Summit 2024 - Meet Crystal Bio at Booth T13
Meet Crystal Pharmatech at 2024 Controlled & Modified Drug Release Summit
Join Crystal Pharmatech for the Sino-American Pharmaceutical Professionals Association (SAPA) NE 26th Annual Conference
Crystal Pharmatech will be in San Diego from June 3-6 at BIO International Convention
Meet Crystal Pharmatech at Chinese Antibody Society 2024 Annual Conference
Meet Crystal Pharmatech at 15th Drug Discovery Strategic Summit (DDSS)
Meet Crystal Pharmatech at Sorption Symposium North America 2024
CPHI North America - Meet Crystal Pharmatech at Booth 1441
Meet Crystal Pharmatech at MIDD+ Boston 2024
Formulation Development: Fastest-to-FIH Without Sacrificing Quality
DCAT WEEK: CMC Discussions
AAPS PharmSci360 - Meet Us at Booth # 2106
Meet the Crystal Pharmatech formulation team next week at CPHI
Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360
Crystal Pharmatech Raring to Go to ChemOutsourcing 2022
CPHI North america - Meet Us at Booth #530
Meet Crystal Pharmatech at AAPS National Biotechnology Conference
DCAT Week 2025
19th WRIB (Workshops on Recent Issues in Bioanalysis)
Knowledge Hub
Technical Articles
Concerned about mRNA -LNP Integrity during International Shipping?
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
Characterization and Evaluation of Amorphous Solid Dispersion-Part 2
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Learn about Drug Eutectic Screening
Crystallization Process Method
Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2)
Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3)
Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1)
Fun Sharing：The Story Between Ice Crystals and Frozen Foods (Part 3)
Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1)
Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2)
Case Study on Development and Production Applications of Amorphous Solid Dispersions - Hot Melt Extrusion
Development and Production Application Case Study of Amorphous Solid Dispersions: Spray Drying
Amorphous Solid Dispersion Technology and the Service Advantages of Crystal Pharmaceutical
ASD Column | Mastering Stable Art: Unveiling Key Factors Influencing Physical Stability of Amorphous Solid Dispersions
ASD Column | How to Select Polymers in Hot-melt Extrusion Process?
ASD Column | Understanding the ASD Preparation Methods and Selecting the Optimal Method for Solution
Polymorphs, Solvatomorphs and Hydrate of Dabrafenib
Shining Glory: Unveiling the "True Eye" behind the Veil of Drug Crystal Forms
Applications of Dynamic Moisture Adsorption in Crystal Research
Application of Granularity Analysis in Crystal Typing Research
A Brief Introduction to Amorphous Solid Dispersion Technology
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Understand ASD Manufacturing Strategies, Choose the Optimal One
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Crystal’s Perspective: Polymorph Patent Landscape of 28 FDA-Approved Small Molecule Drugs in 2024
Presentations
Solid Form Research
Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development
Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals
Effective Development of API Crystallization Processes During Drug Development
Using Thermodynamic Phase Maps in API Crystallization Process Design
Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice
Preclinical and Tox Formulation Development
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
SMART Development of Pre-clinical Candidates
Case Studies
Case Study 1: Indinavir - Early Salt Form Change
Case Study 2: DPC 961 – Form Change On A Fast Track Compound
Case Study 3: Atorvastatin - Crystalline Form Change In Late Development
Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound
Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt
Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base
Assessment of CQA in mRNA-LNP Modality
Parameter Sensitivity with GastroPlus
Whitepaper
Crystal’s Perspective: Polymorph Patent Landscape of 28 FDA-Approved Small Molecule Drugs in 2024
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Parameter Sensitivity with GastroPlus
Amorphous Solid Dispersions
Patent Analysis of Resmetirom
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Detecting Low-Level Crystallinity in ASD-like Samples Using ssNMR Techniques
API Crystallization
Co-crystals
Impact of Solid-state in Early Development
Optimal Preclinical Formulation Development
Salts
Pharmaceutical Solid-state Forms
ASD Series
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Characterization and Evaluation of Amorphous Solid Dispersion - Part 2
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Understand ASD Manufacturing Strategies, Choose the Optimal One
A Brief Introdction to Amorphous Solid Dispersion Technology
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Biologics
Concerned about mRNA -LNP Integrity during International Shipping?
Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality
Critical Quality Attribute D0 Impact in ADC Modality
Assessment of CQA in mRNA-LNP Modality
Sterility Assays in Drug/Device Manufacturing
Webinar Series
Crystal Pharmatech Formulation Forum
Unlocking the Power of AI in Pharmaceutical Development
Utilizing Compaction Simulation for Advancing Oral Dosage Formulation Design
Overcoming Bioavailability Barrier to Deliver Protein Degraders
Overcoming Poor Solubility and Dissolution of Insoluble Molecules
Amorphous Solid Dispersions: Two Heads Are Better Than One
Assessment of Powder Segregation in Direct Compression (DC) Blends: Developing Predictive and PAT Tools
Formulation Design and Development of Fixed Dose Combination Solid Oral Dosage Forms
Drug Delivery and Patient Centric Approaches to Drug Development
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Date:
2:00-3:00 pm EDT, Wednesday,
Whatch on-demand
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Selecting the Right API Form and Formulation
Avoiding Drug Failures: Right First Time; Fast First Time
Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development
Advancements in Analytical Tools for API and DP Characterization
Solid Forms: The Good; The Bad; The Ugly
Utility of Single Crystal in Form and Formulation Selection
Introduction to MicroED Technology and Solutions
Formulation Implications
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
The Purpose Behind Molecules to Medicine
Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication
The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan
Advanced Characterization: Tools for Accelerating Molecules to Medicine
The Tiny-TIM System
Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction
Instrumentation for Electron Diffraction, Applications, and Case Studies
PBPK in Preclinical/FIH Scenarios
Tools for Accessing New Solid Forms
Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer
Exploring the Pharmaceutical Solid State by Molecular Simulation
Crystal Bio Webinar
Analytical Techniques to Assess the mRNA 5' Cap
Careers
Talent Recruitment
Senior Scientist or Associate Principal Scientist, LCMS Platforms
Contact Us
Senior Scientist or Associate Principal Scientist, LBA Platforms
Sr or Associate Principal Scientist Flow_PCR_Elispot Platforms
Last updated: 2025/05/13
Homepage